PDS Biotechnology logo

PDSB - PDS Biotechnology News Story

$5.69 -0.0  -0.4%

Last Trade - 9:00pm

Small Cap
Market Cap £119.8m
Enterprise Value £68.3m
Revenue £n/a
Position in Universe 4961st / 7405

PDS Biotechnology to Present Results from its Phase 1 Trial of PDS0101 and the Phase 2 Clinical Strategy in Patients with Advanced HPV-Associated Malignancies

Mon 28th September, 2020 1:30pm
For best results when printing this announcement, please click on link below:

FLORHAM PARK, N.J., Sept. 28, 2020 (GLOBE NEWSWIRE) -- PDS Biotechnology
Corporation (“PDS Biotech” or the “Company”) (Nasdaq: PDSB), a
clinical-stage immunotherapy company developing novel cancer therapies and
infectious disease vaccines based on the Company’s proprietary Versamune(®)
T-cell activating technology, today announced that its Chief Medical Officer,
Lauren V. Wood, M.D. will present key data from the company’s previously
reported Phase 1 trial of PDS0101 and planned Phase 2 clinical studies in
patients with advanced HPV-associated malignancies at the World Vaccine
Congress, being held virtually September 28 – October 1, 2020.

 Abstract:  Versamune (®)Plus Multi-Epitopic HPV16 Peptides in the Treatment of HPV-Associated Cancers   
 Session:   Cancer & Immunotherapy, Viral Associated Cancers                                             
 Date:      Wednesday, September 30, 2020                                                                
 Time:      2:05 p.m. ET                                                                                 

About PDS Biotechnology

PDS Biotech is a clinical-stage immunotherapy company with a growing pipeline
of cancer immunotherapies and infectious disease vaccines based on the
Company’s proprietary Versamune® T-cell activating technology platform.
Versamune(®) effectively delivers disease-specific antigens for in vivo
uptake and processing, while also activating the critical type 1 interferon
immunological pathway, resulting in production of potent disease-specific
killer T-cells as well as neutralizing antibodies. PDS Biotech has engineered
multiple therapies, based on combinations of Versamune(®) and
disease-specific antigens, designed to train the immune system to better
recognize disease cells and effectively attack and destroy them.

Forward Looking Statements

This press release includes forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995 on our current
expectations and projections about future events. In some cases,
forward-looking statements can be identified by terminology such as "may,"
"should," "potential," "continue," "expects," "anticipates," "intends,"
"plans," "believes," "estimates," and similar expressions. These statements
are based upon current beliefs, expectations, and assumptions and include
statements regarding the proposed public offering and anticipated closing.
These statements are subject to a number of risks and uncertainties, many of
which are difficult to predict, including market conditions, whether the
proposed offering is completed, the satisfaction of customary closing
conditions related to the proposed offering and the other factors described in
PDS Biotech’s filings with the SEC. The information in this release is
provided only as of the date of this release, and PDS Biotech undertakes no
obligation to update any forward-looking statements contained in this release
based on new information, future events, or otherwise, except as required by

Media & Investor Relations Contact:

Deanne Randolph
PDS Biotechnology
Phone: +1 (908) 517-3613
Email: drandolph@pdsbiotech.com

James Salierno
The Ruth Group
Phone: +1 (646) 536-7028 / +1 (973) 255-8361
Email: jsalierno@theruthgroup.com


GlobeNewswire, Inc. 2020
© Stockopedia 2022, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.